IDL Biotech has now received its first order from the company's distributor in Uganda, Medilink Lab & Surgical Ltd. The order refers to TUBEX® TF, IDL Biotech's rapid test for typhoid fever. Uganda will thus be the third country in Africa to which the company...
IDL Biotech continues to expand in Africa. IDL Biotech has signed a distributor agreement with Res Health Consult Ltd covering Ghana. The agreement covers the sale of TUBEX® TF. Since its launch in Africa, the company has focused on finding the right partners for...
IDL Biotech currently has a number of ongoing clinical studies both internationally and in Sweden, with the aim of demonstrating the clinical benefit of UBC® Rapid in bladder cancer and having the test included as a complement in the follow-up of patients with bladder...
IDL Biotech continues to expand in Africa. Today, IDL Biotech has signed a distributor agreement with Roi Scientific Ltd covering Rwanda, South Sudan and Somalia. The agreement covers the sale of TUBEX® TF. Since its launch in Africa, the company has focused on...
As previously informed, at the end of 2019, IDL Biotech signed a cooperation agreement with the Chinese company Zecen Biotech, regarding automation of the tumor marker TPS® on all Zecen Biotech's instruments. The development project has proceeded very well and the...
In 2019, IDL Biotech submitted a so-called Pre-submission request to the US FDA (United States Food and Drug Administration) this was done to ensure the future approval of UBC® Rapid, the companys rapid diagnostic test for bladder cancer. As of now, the company is...
IDL Biotech has appointed Subyung Park as Business Development Manager Asia with a focus on the product TUBEX® TF. Read the press release here
A publication presented in Entropy shows the value of UBC® Rapid Read the press release here and here
IDL has signed a new distribution agreement in Uganda Read the press release here
Achieving accurate laboratory diagnosis of typhoid fever: a review and meta-analysis of TUBEX® TF clinical performance. Read the article here: Read the press release here:
